Interventional cardiology - Bolus-only versus bolus plus infusion of glycoprotein IIb/IIIa inhibitors during percutaneous coronary intervention

被引:27
作者
Kini, Annapoorna S. [1 ]
Chen, Victor H. T. [1 ]
Krishnan, Prakash [1 ]
Lee, Paul [1 ]
Kim, Michael C. [1 ]
Mares, Angelica [1 ]
Suleman, Javed [1 ]
Moreno, Pedro R. [1 ]
Sharma, Samin K. [1 ]
机构
[1] Mt Sinai Med Ctr, Cardiovasc Inst, Cardiac Catheterizat Lab, New York, NY 10029 USA
关键词
D O I
10.1016/j.ahj.2008.04.019
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background The present study was done to analyze if glycoprotein IIb/IIIa inhibitors (GPI) bolus-only will reduce vascular/bleeding complications and cost with similar major adverse cardiac events (MACE) when compared with GPI bolus + infusion. Evidence-based therapy of GPI inhibitors during percutaneous coronary intervention (PCI) incorporates intravenous bolus followed by 12 to 18 hours of infusion. However, GPI bolus + infusion may increase vascular/bleeding complications and may not reduce MACE when compared with GPI bolus-only. Methods From January 1, 2003, to December 31, 2004, 2,629 consecutive patients received GPI during PCI at a single center. Of these, 1,064 patients received GPI bolus + infusion in 2003 and were compared with 1,565 patients that received GPI bolus-only in 2004. Baseline characteristics were similar in both groups. Results Patients receiving GPI bolus-only had reduced vascular/bleeding complications when compared with bolus + infusion (4.9% vs 7%, P < .05, odds ratio 0.62, 95% confidence interval 0.45-0.89). Furthermore, ischemic complications were similar in both groups, including periprocedural creatine kinase-MB enzyme release (12.8% vs 15.3%, P = NS), MACE at 30 days (3.2% vs 3%, P = NS), and death and myocardial infarction at 1 year (7.1 % vs 7.8%, P = NS). In addition, GPI bolus-only reduced cost in US dollars ($323 vs $706, P < .001) and increased ambulatory PCI (13.1% vs 3.2%, P < .01), with reduced length of stay (1.1 vs 1.6 days, P < .01), when compared with GPI bolus + infusion. Conclusions Glycoprotein inhibitor bolus-only reduces vascular/bleeding complications with similar MACE and reduced cost when compared with GPI bolus + infusion. In addition, GPI bolus-only improved ambulatory PCI and reduced length of stay. These results are consistent with a safer and cost-effective strategy for bolus-only when GPI therapy is considered during PCI.
引用
收藏
页码:513 / 519
页数:7
相关论文
共 38 条
  • [1] A randomized study comparing same-day home discharge and abciximab bolus only to overnight hospitalization and abciximab bolus and infusion after transradial coronary stent implantation
    Bertrand, Olivier F.
    De Larochelliere, Robert
    Rodes-Cabau, Josep
    Proulx, Guy
    Gleeton, Onil
    Nguyen, Can Manh
    Dery, Jean-Pierre
    Barbeau, Gerald
    Noel, Bernard
    Larose, Eric
    Poirier, Paul
    Roy, Louis
    [J]. CIRCULATION, 2006, 114 (24) : 2636 - 2643
  • [2] USE OF A MONOCLONAL-ANTIBODY DIRECTED AGAINST THE PLATELET GLYCOPROTEIN IIB/IIIA RECEPTOR IN HIGH-RISK CORONARY ANGIOPLASTY
    CALIFF, RM
    SHADOFF, N
    VALETT, N
    BATES, E
    GALEANA, A
    KNOPF, W
    SHAFTEL, J
    BENDER, MJ
    AVERSANO, T
    RAQUENO, J
    GURBEL, P
    COWFER, J
    COHEN, M
    CROSS, P
    BITTL, J
    EDDINGS, K
    TAYLOR, M
    DEROSA, K
    HATTEL, L
    COOPER, L
    ESHELMAN, B
    FINTEL, D
    NIEMYSKI, P
    KLEIN, L
    KENNEDY, H
    THORNTON, T
    KEREIAKES, D
    MARTIN, L
    ANDERSON, L
    HIGBY, N
    ELLIS, S
    BREZINA, K
    GEORGE, B
    CHAPEKIS, A
    SMITH, D
    ANWAR, A
    GERBER, TL
    PRITCHARD, GL
    MYLER, R
    SHAW, R
    MURPHY, M
    WARD, K
    MADIGAN, NP
    BLANKENSHIP, J
    HALBERT, M
    FLANAGAN, C
    TANNENBAUM, M
    POLICH, M
    STEVENSON, C
    TCHENG, J
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1994, 330 (14) : 956 - 961
  • [3] A NEW MURINE MONOCLONAL-ANTIBODY REPORTS AN ACTIVATION-DEPENDENT CHANGE IN THE CONFORMATION AND OR MICROENVIRONMENT OF THE PLATELET GLYCOPROTEIN IIB/IIIA COMPLEX
    COLLER, BS
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1985, 76 (01) : 101 - 108
  • [4] A RANDOMIZED COMPARISON OF CORONARY-STENT PLACEMENT AND BALLOON ANGIOPLASTY IN THE TREATMENT OF CORONARY-ARTERY DISEASE
    FISCHMAN, DL
    LEON, MB
    BAIM, DS
    SCHATZ, RA
    SAVAGE, MP
    PENN, I
    DETRE, K
    VELTRI, L
    RICCI, D
    NOBUYOSHI, M
    CLEMAN, M
    HEUSER, R
    ALMOND, D
    TEIRSTEIN, PS
    FISH, RD
    COLOMBO, A
    BRINKER, J
    MOSES, J
    SHAKNOVICH, A
    HIRSHFELD, J
    BAILEY, S
    ELLIS, S
    RAKE, R
    GOLDBERG, S
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1994, 331 (08) : 496 - 501
  • [5] Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels
    Hamm, CW
    Heeschen, C
    Goldmann, B
    Vahanian, A
    Adgey, J
    Miguel, CM
    Rutsch, W
    Berger, J
    Kootstra, J
    Simoons, ML
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1999, 340 (21) : 1623 - 1629
  • [6] Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents
    Iakovou, I
    Schmidt, T
    Bonizzoni, E
    Ge, L
    Sangiorgi, GM
    Stankovic, G
    Airoldi, F
    Chieffo, A
    Montorfano, M
    Carlino, M
    Michev, I
    Corvaja, N
    Briguori, C
    Gerckens, U
    Grube, E
    Colombo, A
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2005, 293 (17): : 2126 - 2130
  • [7] Influence of treatment duration with a 600-mg dose of clopidogrel before percutaneous coronary revascularization
    Kandzari, DE
    Berger, PB
    Kastrati, A
    Steinhubl, SR
    Mehilli, J
    Dotzer, F
    ten Berg, JM
    Neumann, FJ
    Bollwein, H
    Dirschinger, J
    Schömig, A
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2004, 44 (11) : 2133 - 2136
  • [8] ROLES OF THROMBIN AND PLATELET MEMBRANE GLYCOPROTEIN-IIB/IIIA IN PLATELET-SUBENDOTHELIAL DEPOSITION AFTER ANGIOPLASTY IN AN EXVIVO WHOLE ARTERY MODEL
    KAPLAN, AV
    LEUNG, LLK
    LEUNG, WH
    GRANT, GW
    MCDOUGALL, IR
    FISCHELL, TA
    [J]. CIRCULATION, 1991, 84 (03) : 1279 - 1288
  • [9] Time course, magnitude, and consistency of platelet inhibition by abciximab, tirofiban, or eptifibatide in patients with unstable angina pectoris undergoing percutaneous coronary intervention
    Kereiakes, DJ
    Broderick, TM
    Roth, EM
    Whang, D
    Shimshak, T
    Runyon, JP
    Hattemer, C
    Schneider, J
    Lacock, P
    Mueller, M
    Abbottsmith, CW
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 1999, 84 (04) : 391 - 395
  • [10] Reduction in periprocedural enzyme elevation by abciximab after rotational atherectomy of type B2 lesions:: Results of the Rota ReoPro randomized trial
    Kini, A
    Reich, D
    Marmur, JD
    Mitre, CA
    Sharma, SK
    [J]. AMERICAN HEART JOURNAL, 2001, 142 (06) : 965 - 969